<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154539">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01673191</url>
  </required_header>
  <id_info>
    <org_study_id>RCA2012</org_study_id>
    <nct_id>NCT01673191</nct_id>
  </id_info>
  <brief_title>A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus</brief_title>
  <official_title>A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retinal Consultants of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Retinal Consultants of Arizona</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a need to find an effective therapy for diabetic patients who develop macular edema
      after cataract surgery. The objective of this study is to assess the safety and efficacy of
      the OZURDEX® intraocular implant in patients with diabetes mellitus, who develop macular
      edema after cataract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of patients with significant decrease in OCT (e.g., 50-100 µm) following treatment with OZURDEX®.</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Macular Edema After Cataract Surgery in Patients With Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>OZURDEX intraocular implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZURDEX (dexamethasone posterior segment drug delivery system (DEX PS DDS), 0.7 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid plus NSAID eye drop combination therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NSAID eye drop: Acular LS Steriod eye drop: Pred Forte</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone intravitreal implant</intervention_name>
    <arm_group_label>OZURDEX intraocular implant</arm_group_label>
    <other_name>OZURDEX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroid plus NSAID eye drop combination therapy</intervention_name>
    <arm_group_label>Steroid plus NSAID eye drop combination therapy</arm_group_label>
    <other_name>Acular LS and Pred Forte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has diagnosis of Diabetes Mellitus, Type I or II.

          -  Patient has experienced the development of macular edema following cataract surgery
             in at least one eye.

          -  Patient has had cataract surgery within 90 days prior to the screening visit.

        Exclusion Criteria:

          -  Patient has other significant ocular disease in study eye, including glaucoma.

          -  Patient has any active infection in the study eye.

          -  Patient has uncontrolled systemic illness (i.e., uncontrolled blood pressure,
             uncontrolled diabetes mellitus).

          -  Patient has experienced a significant increase in intraocular pressure following a
             prior treatment with topical or intravitreal steroidal medication.

          -  Patient has received the OZURDEX® implant before in the study eye.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pravin U Dugel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retinal Consultants of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retinal Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Mobley</last_name>
      <phone>602-222-2221</phone>
      <phone_ext>4152</phone_ext>
      <email>smobley@retinalconsultantsaz.com</email>
    </contact>
    <investigator>
      <last_name>Pravin Dugel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Derek Kunimoto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edward Quinlan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaime Gaitan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Goldenberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karim Jamal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sachin Mehta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Madhavi Kurli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 19, 2014</lastchanged_date>
  <firstreceived_date>August 22, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Capsule Opacification</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
